References
- Shapiro NI, Howell M, Talmor D. A blueprint for a sepsis protocol. Acad Emerg Med 2005;12:352–9
- Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis [The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine]. Chest 1992;101:1644–55
- Sands K, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers. J Am Med Assoc 1997;278:234–40
- Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. New Engl J Med 2001;344:699–709
- Bernard GR, Margolis BD, Shanies HM, et al. Extended Evaluation of Recombinant Human Activated Protein C United States trial (ENHANCE US): a single-arm, phase 3B, multi-center study of drotrecogin alfa (activated) in severe sepsis. Chest 2004;125:2206–16
- Wheeler A, Steingrub J, Schmidt G, et al. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison to a controlled clinical trial. Crit Care Med [under review]
- Wheeler A, Steingrub J, Linde-Zwirble W, et al. Prompt administration of drotrecogin alfa (activated) is associated with improved survival [abstract]. Crit Care Med 2003;31:A120
- Vincent J-L, O’Brien Jr J, Wheeler A, et al. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. Crit Care 2006, 10:R74 [oi:10.1186/cc4909]
- Teres D, Rapoport J, Lemeshow S, et al. Effects of severity of illness on resource use by survivors and nonsurvivors of severe sepsis at intensive care unit admission. Crit Care Med 2002;30:2413–9
- Rapoport J, Teres D, Zhao Y, et al. Length of stay data as a guide to hospital economic performance for ICU patients. Med Care 2003;41:386–97
- Dasta JF, McLaughlin TP, Modey SH, et al. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med 2005;33:1266–71
- Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcomes, and associated costs of care. Crit Care Med 2001;29:1303–10
- Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999;20: 125–44
- Braun LA, Riedel AA, Cooper LM. Severe sepsis in managed care: analysis of incidence, one-year mortality and associated costs of care. JMCP 2004;10:521–30
- Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858–73 [doi: 10.1097/01. ccm.0000117317.18092.e4]
- Alberti C, Brun-Buisson C, Chevret S, et al. Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med 2005;171:461–8 [doi: 10.1164/rccm.200403–324oc]
- Johnston JA. Determinants of mortality in patients with severe sepsis. Med Decis Making 2005;25:374–86 [doi: 10.1177/0272 989x05278933]
- Kumar A, Roberts D, Wood K, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589–96 [doi:10.1097/01.ccm.0000217961.75225.e9]